MLA
IMNM icon

MB, Levis & Associates’s Immunome IMNM Stock Holding History

MB, Levis & Associates’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.3K Hold
2,373
– – 0.02% 107
2026
Q1 		$51.9K Hold
2,373
– – 0.02% 104
2025
Q4 		$51K Hold
2,373
– – 0.02% 103
2025
Q3 		$27.8K Hold
2,373
– – 0.01% 129
2025
Q2 		$22.1K Hold
2,373
– – 0.01% 163
2025
Q1 		$16K Hold
2,373
– – 0.01% 171
2024
Q4 		$25.2K Hold
2,373
– – 0.01% 149
2024
Q3 		$34.7K Hold
2,373
– – 0.02% 134
2024
Q2 		$28.7K Hold
2,373
– – 0.02% 143
2024
Q1 		$58.6K Hold
2,373
– – 0.03% 111
2023
Q4 		$25.4K Hold
2,373
– – 0.01% 145
2023
Q3 		$19.8K Hold
2,373
– – 0.01% 159
2023
Q2 		$18.8K Hold
2,373
– – 0.01% 162
2023
Q1 		$11.8K Hold
2,373
– – 0.01% 189
2022
Q4 		$5.24K Buy
+2,373
New +$9.56K ﹤0.01% 206

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

MB, Levis & Associates's IMNM Position: Q2 2026 in Review

MB, Levis & Associates held its Immunome (IMNM) position steady in Q2 2026 at 2,373 shares worth $50.3K. The position accounts for 0.02% of the portfolio, ranked #107.

MB, Levis & Associates first reported a position in IMNM in Q4 2022 and has held it in 15 quarters since. The position peaked at $58.6K in Q1 2024. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • MB, Levis & Associates held 2,373 shares of Immunome worth $50.3K as of Q2 2026.
  • MB, Levis & Associates left its Immunome share count unchanged in Q2 2026.
  • Immunome made up 0.02% of MB, Levis & Associates's portfolio in Q2 2026, its #107 holding.
  • MB, Levis & Associates first reported a position in Immunome in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's Immunome position peaked at $58.6K in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.